arrow
A

Annunziato Anghelone

comprehensive cancer center
H指数:4
被引数:76

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study

真实世界证据:regorafenib剂量递增与固定剂量在难治性转移性结直肠癌中的比较:ReTrITA研究的结果

2025-10-140
OAAI
Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

阿柏西普为基础和贝伐珠单抗为基础的二线方案在转移性结直肠癌患者中的应用:一项多中心队列研究的倾向性评分加权分析

2025-01-020
OAAI
Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis
2024-04-131
OAAI
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations

接受一线免疫治疗的转移性肾细胞癌患者基于红细胞的血液预后评分的外部验证

2024-02-163
OAAI
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OA
Aflibercept-based and bevacizumab-based second-line regimens in patients with RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort
2023-06-010
OAAI
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients

在RAS/BRAF野生型转移性结直肠癌患者中,根据原发肿瘤部位,基于三线抗EGFR治疗与瑞戈非尼或三氟尿苷/替匹拉西的疗效比较

2023-02-211
OAAI
Conversion Therapy With Encorafenib and Cetuximab for Chemo-Refractory BRAF V600E-Mutated Liver-Limited Colorectal Cancer Metastasis: The First Case Report

恩可非尼和西妥昔单抗转化治疗化疗难治性BRAF V600E-Mutated肝限制性结直肠癌转移: 第一例报告

2021-12-010
PRE
Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics

转移性结直肠癌的基线影像组学特征: 与转移部位和临床病理特征的相关性

2020-07-010
OAAI